Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
468530.KQ
STRONG SELLPROTEINA · Healthcare · South Korea · $261M · Avg Vol: $2M/d
1
StockRankQ
38
V
21
M
11
P/E (TTM)
—
ROE
-31.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Proteina Co.,Ltd. develops protein-protein interaction profiling technology. The company offers technology that confirms the real-time activation of cancer signal pathways by directly seeing the relevant proteins, predicts the efficacy of drugs, and enables doctors to select which inhibitor to...
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 306,499 | 380,561 | 2M | 2M | 85.1% |
| EPS | -8.83 | -3.54 | -0.68 | -0.60 | — |
| Shares | 11M | 11M | 11M | 11M | +0.8% |
| Debt | 254,199 | 126,835 | 665,124 | 570,425 | 30.9% |
| Equity | -20M | -35M | 10M | 19M | 80.1% |
| Op CF | -2M | -4M | -4M | -5M | — |
| Inv CF | 2M | -7M | 12M | -11M | — |
| Fin CF | -116,794 | 11M | -135,903 | 14M | — |
Loading...
PRICE (1M)-36.3%
SMA 50SMA 200
Close
$22.55
RSI (14)
35.6
52W High
$79.06
From 52W High
0.3%
SCORE BREAKDOWN
Quality
38
ROIC
-29.7%22.9
ROE
-31.8%24.4
GP/Assets
4.8%18.3
Op. Margin
0.0%40.4
FCF/Assets
-30.2%9.6
Piotroski
—28.7
Int. Cover
-50.0x6.4
D/E Ratio
0.03x78.5
Current Ratio
15.15x92.8
Value
21
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
12.4x8.1
P/S
132.1x6.7
Div Yield
—N/A
Momentum
11
52W High %
29%4.9
RS 6M
-182%0.1
SMA 50/200
0.78x11.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$261M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 468530.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 468530.KQ | PROTEINA(you) | $261M | 1 | STRONG SELL |
| 493280.KQ | IMBiologics | $259M | 2 | STRONG SELL |
| 424870.KQ | ImmuneOncia | $252M | 1 | STRONG SELL |
| 372320.KQ | Curocell | $285M | 1 | STRONG SELL |
| 287840.KQ | IntoCell, Inc. | $227M | 2 | STRONG SELL |
| 376270.KQ | HEM Pharma Inc. | $203M | 3 | STRONG SELL |
| 199800.KQ | ToolGen Incorporated | $266M | 11 | STRONG SELL |
| 304360.KQ | S.Biomedics Co., Ltd. | $225M | 9 | STRONG SELL |
| 228760.KQ | Genomictree Inc. | $216M | 9 | STRONG SELL |
| 215600.KQ | SillaJen, Inc. | $233M | 13 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%